[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline - Slideshow",
    "summary": "2025-11-10. The following slide deck was published by Regeneron Pharmaceuticals, Inc.",
    "url": "https://finnhub.io/api/news?id=935d4884dc048604f8b913c6d932b9b9d2f3371266f1ad337112928084b96590",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762812167,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline - Slideshow",
      "id": 137424698,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "2025-11-10. The following slide deck was published by Regeneron Pharmaceuticals, Inc.",
      "url": "https://finnhub.io/api/news?id=935d4884dc048604f8b913c6d932b9b9d2f3371266f1ad337112928084b96590"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients",
    "summary": "The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.",
    "url": "https://finnhub.io/api/news?id=cd1dcc678f221e9a9dd9e8e12e6c2121f6aed9edece2003400de7d273c796396",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762809600,
      "headline": "Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients",
      "id": 137415864,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.",
      "url": "https://finnhub.io/api/news?id=cd1dcc678f221e9a9dd9e8e12e6c2121f6aed9edece2003400de7d273c796396"
    }
  },
  {
    "ts": null,
    "headline": "European Equities Close Sharply Higher in Monday Trading on Hopes for End to US Government Shutdown",
    "summary": "European stock markets surged in Monday trading on investor optimism that the end of the US governme",
    "url": "https://finnhub.io/api/news?id=57ea6bb4466ef981ceddacd83a4066c1945e192a873bedfbeff6f6d911b544b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762795334,
      "headline": "European Equities Close Sharply Higher in Monday Trading on Hopes for End to US Government Shutdown",
      "id": 137396757,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "European stock markets surged in Monday trading on investor optimism that the end of the US governme",
      "url": "https://finnhub.io/api/news?id=57ea6bb4466ef981ceddacd83a4066c1945e192a873bedfbeff6f6d911b544b6"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript",
    "summary": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline November 10, 2025 8:30 AM ESTCompany...",
    "url": "https://finnhub.io/api/news?id=9df7072de479d37de3fa7ea137bce3abefd843bc7896daf030e1867d51118d21",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762785091,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript",
      "id": 137399540,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline November 10, 2025 8:30 AM ESTCompany...",
      "url": "https://finnhub.io/api/news?id=9df7072de479d37de3fa7ea137bce3abefd843bc7896daf030e1867d51118d21"
    }
  },
  {
    "ts": null,
    "headline": "Dupixent set for ninth US approval after Phase III AFRS success",
    "summary": "Patients treated with Dupixent were 92% less likely to need corticosteroids or surgery.",
    "url": "https://finnhub.io/api/news?id=3fd489fec1dac934ba8e28415f712ecf382a485f755808454fe61175913e0409",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762775814,
      "headline": "Dupixent set for ninth US approval after Phase III AFRS success",
      "id": 137395177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Patients treated with Dupixent were 92% less likely to need corticosteroids or surgery.",
      "url": "https://finnhub.io/api/news?id=3fd489fec1dac934ba8e28415f712ecf382a485f755808454fe61175913e0409"
    }
  },
  {
    "ts": null,
    "headline": "Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks",
    "summary": "Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.",
    "url": "https://finnhub.io/api/news?id=96ab171908f1c9f583e936d8a4c16ee315c826613c879953c4c1977bbe735c7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762766705,
      "headline": "Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks",
      "id": 137437951,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.",
      "url": "https://finnhub.io/api/news?id=96ab171908f1c9f583e936d8a4c16ee315c826613c879953c4c1977bbe735c7c"
    }
  },
  {
    "ts": null,
    "headline": "UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)",
    "summary": "REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron’s and Bayer’s injun",
    "url": "https://finnhub.io/api/news?id=955792631426ea613be5784a0f438f419b6c7e79e347911a0f68b7e245e82182",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762765200,
      "headline": "UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)",
      "id": 137395178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron’s and Bayer’s injun",
      "url": "https://finnhub.io/api/news?id=955792631426ea613be5784a0f438f419b6c7e79e347911a0f68b7e245e82182"
    }
  }
]